Clinical Trial Update: Anti-CD38 Antibody Treating Pediatric Primary Immune Thrombocytopenia (ITP) [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial is evaluating an anti-CD38 antibody for treating pediatric primary immune thrombocytopenia (ITP). The study is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Immune Thrombocytopenia

Drugs mentioned

• Anti-CD38 antibody

Snippet

Sponsor: Institute of Hematology & Blood Diseases Hospital, China | Conditions: Immune Thrombocytopenia, Treatment | Phase 2 | Status: RECRUITING